天新药业: 2025年半年度报告摘要

Company Overview - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported total assets of approximately 5.75 billion RMB at the end of the reporting period, reflecting a 2.70% increase from the previous year [1] - The net assets attributable to shareholders increased by 1.41% to approximately 4.68 billion RMB [1] Financial Performance - The company's operating revenue for the reporting period was approximately 1.12 billion RMB, representing a 5.23% increase compared to the same period last year [1] - Total profit amounted to approximately 424.59 million RMB, up by 3.54% year-on-year [1] - The net profit attributable to shareholders was approximately 356.01 million RMB, a 3.14% increase from the previous year [1] - The net profit after deducting non-recurring gains and losses was approximately 336.28 million RMB, reflecting a 2.15% increase [1] - The net cash flow from operating activities was approximately 342.00 million RMB, a significant increase of 75.16% compared to the previous year [1] - The weighted average return on net assets decreased by 0.50 percentage points to 7.42% [1] - Basic and diluted earnings per share were both 0.82 RMB, an increase of 3.80% from the previous year [1] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,820 [1] - The largest shareholder, Xu Jiangnan, holds 46.51% of the shares, followed by Xu Jing with 13.50% and Wang Guangtian with 12.98% [2] - Xu Jiangnan and Xu Jing are identified as the actual controllers of the company [2]